MicroQin Partners with NIAID to Advance Anti-Viral Treatment Development

The global fight against viral diseases has taken a significant step forward as MicroQin, a biotechnology company, has signed a collaboration agreement with the National Institute of Allergy and Infectious Diseases (NIAID). This partnership aims to accelerate the development of new anti-viral treatments, addressing urgent public health needs. The collaboration combines MicroQin’s expertise in drug discovery with NIAID’s extensive research capabilities, promising to bring innovative therapies closer to patients.

MicroQin and NIAID collaborate on antiviral research